Soare Georgiana R, Soare Costin A
Hopital Femme Mere Enfant, Hospice Civile de Lyon, Lyon, France.
QPathology, Boston, MA, USA.
Discoveries (Craiova). 2019 Mar 31;7(1):e91. doi: 10.15190/d.2019.4.
1 in 8 women will be affected by breast cancer, which is the most diagnosed malignancy among women. Although breast cancer was regarded as "immunologically cold", recent studies demonstrate that immunotherapy can be successful employed in combination regimens for the treatment of triple negative breast cancer, an aggressive type of breast cancer without many treatment options available. In March 2019, the US Food and Drug Administration granted accelerated approval for the first immunotherapy-based regimen comprising atezolizumab in combination with protein-bound paclitaxel for patients with advanced metastatic TNBC, expressing programmed cell death-ligand 1 (PD-L1) and without previous systemic treatment for metastatic disease. This immunotherapy-based regimen is not only a promising therapy for the TNBC patients, but it also represents an inspiring proof of concept for the development of more efficient advanced immunotherapy-based strategies for breast cancer treatment in the future.
八分之一的女性会受到乳腺癌的影响，乳腺癌是女性中诊断出最多的恶性肿瘤。尽管乳腺癌曾被视为“免疫冷肿瘤”，但最近的研究表明，免疫疗法可成功用于联合治疗方案，以治疗三阴性乳腺癌，这是一种侵袭性乳腺癌，可用的治疗选择不多。2019年3月，美国食品药品监督管理局加速批准了首个基于免疫疗法的方案，该方案包括阿替利珠单抗与蛋白结合型紫杉醇联合使用，用于治疗晚期转移性三阴性乳腺癌患者，这些患者表达程序性细胞死亡配体1（PD-L1）且此前未接受过转移性疾病的全身治疗。这种基于免疫疗法的方案不仅是三阴性乳腺癌患者的一种有前景的治疗方法，而且它还代表了一个鼓舞人心的概念验证，为未来开发更有效的基于免疫疗法的晚期乳腺癌治疗策略提供了依据。
